<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03737695</url>
  </required_header>
  <id_info>
    <org_study_id>AURORA US</org_study_id>
    <secondary_id>NCI-2018-02144</secondary_id>
    <secondary_id>AURORA</secondary_id>
    <secondary_id>18-001910</secondary_id>
    <secondary_id>AURORA US</secondary_id>
    <secondary_id>P30CA015083</secondary_id>
    <nct_id>NCT03737695</nct_id>
  </id_info>
  <brief_title>Clinical Information and Biospecimen Collection From Patients With Recurrent or Stage IV Breast Cancer</brief_title>
  <official_title>AURORA US: Prospective Biospecimen Repository in Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial collects clinical information and tissue and blood samples from patients with&#xD;
      breast cancer that has come back or is stage IV. Collecting clinical information and&#xD;
      biospecimen samples to create a registry may help doctors better understand the mechanism of&#xD;
      tumor spread and determine why people respond differently to specific cancer treatments.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To create a comprehensive registry that includes patient demographics, clinical and&#xD;
      histopathological data, blood samples, and tissue specimens from the primary tumor and&#xD;
      metastatic sites of patients with metastatic breast cancer to improve our understanding of&#xD;
      the mechanisms of tumor metastasis and therapeutic resistance.&#xD;
&#xD;
      II. To conduct genomic studies of paired primary tumors and distant metastatic sites.&#xD;
&#xD;
      III. To conduct genomic studies of paired distant metastatic sites obtained during the course&#xD;
      of an individual's disease.&#xD;
&#xD;
      IV. To conduct genomic studies of cell free deoxyribonucleic acid (DNA), circulating tumor&#xD;
      cell (CTC) derived DNA, germline DNA, and immune based markers in the peripheral circulation.&#xD;
&#xD;
      SECONDARY OBJECTIVE:&#xD;
&#xD;
      I. To evaluate the concordance between DNA sequencing results obtained from a clinically&#xD;
      available assay and those obtained specifically for research purposes.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients' archival and newly collected tissue and blood samples are collected periodically&#xD;
      for genetic testing. Patients also undergo collection of clinical information within 30 days&#xD;
      of biopsy procedure and every 4 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 16, 2019</start_date>
  <completion_date type="Anticipated">November 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 15, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Comprehensive biorepository creation</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Will create a comprehensive biorepository that includes blood, archival tissue, fresh tissue, and linked molecular and clinical data from patients with recurrent and/or metastatic breast cancer.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Anatomic Stage IV Breast Cancer AJCC v8</condition>
  <condition>Ascites</condition>
  <condition>Invasive Breast Carcinoma</condition>
  <condition>Metastatic Breast Carcinoma</condition>
  <condition>Prognostic Stage IV Breast Cancer AJCC v8</condition>
  <condition>Recurrent Breast Carcinoma</condition>
  <arm_group>
    <arm_group_label>Ancillary-Correlative (biospecimen, clinical info collection)</arm_group_label>
    <description>Patients' archival and newly collected tissue and blood samples are collected periodically for genetic testing. Patients also undergo collection of clinical information within 30 days of biopsy procedure and every 4 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Biospecimen Collection</intervention_name>
    <description>Undergo biospecimen collection</description>
    <arm_group_label>Ancillary-Correlative (biospecimen, clinical info collection)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Medical Chart Review</intervention_name>
    <description>Undergo clinical information collection</description>
    <arm_group_label>Ancillary-Correlative (biospecimen, clinical info collection)</arm_group_label>
    <other_name>Chart Review</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Tissue, blood&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with recurrent and/or metastatic breast cancer of all tumor subtypes&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed or suspected invasive breast cancer&#xD;
&#xD;
          -  Radiographic evidence of distant metastatic disease&#xD;
&#xD;
          -  Clinical or radiographic evidence of disease progression OR presenting with de novo&#xD;
             stage IV disease&#xD;
&#xD;
          -  Available archived tissue from the initial breast primary (formalin fixed paraffin&#xD;
             embedded [FFPE] tissue is acceptable; fresh frozen tissue is preferred if available)&#xD;
&#xD;
          -  Accessible lesion representative of recurrent or metastatic breast cancer for biopsy&#xD;
&#xD;
               -  Type 1 specimen collection: Patients undergoing a clinically directed tissue&#xD;
                  biopsy or tissue collection who are willing to have additional specimens taken&#xD;
                  for research during the same procedure. Sites for tissue acquisition may include&#xD;
                  the breast, skin/chest wall, lymph node/soft tissue, liver, bone, lung, brain,&#xD;
                  pleural fluid, and ascites as needed for routine clinical care&#xD;
&#xD;
               -  Type 2 specimen collection: Patients undergoing a tissue biopsy or tissue&#xD;
                  collection for research purposes only. Sites for tissue acquisition include the&#xD;
                  breast, skin/chest wall, lymph node/soft tissue, liver, bone, pleural fluid, and&#xD;
                  ascites. Research directed lung biopsies and brain biopsies are not permitted.&#xD;
                  Procedures for tissue acquisition are restricted to those performed under local&#xD;
                  anesthesia or intravenous (IV) conscious sedation; biopsies that require general&#xD;
                  anesthesia are not permitted in this situation&#xD;
&#xD;
          -  Previous cytologic confirmation of malignant pleural effusion or ascites if that is&#xD;
             the planned source of fresh specimen collection for study participation&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-2&#xD;
&#xD;
          -  Ability to understand and the willingness to sign an informed consent document&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Concurrent disease or condition that in the opinion of the treating oncologist or the&#xD;
             provider performing the biopsy procedure renders the patient inappropriate for study&#xD;
             participation&#xD;
&#xD;
          -  Concurrent serious medical or psychiatric disorder that may interfere with the&#xD;
             subject's safety during the biopsy or tissue collection procedure&#xD;
&#xD;
          -  Dementia, altered mental status, or any psychiatric condition that would prohibit the&#xD;
             understanding or rendering of informed consent&#xD;
&#xD;
          -  History of a serious or life-threatening allergic reaction to local anesthetics (e.g.,&#xD;
             lidocaine, xylocaine) used during a biopsy procedure&#xD;
&#xD;
          -  Pregnancy (due to the risk of conscious sedation or anesthesia to mother and fetus)&#xD;
&#xD;
          -  Any condition or laboratory finding that in the opinion of the treating oncologist or&#xD;
             the provider performing the biopsy procedure would make participation in this protocol&#xD;
             hazardous for the patient&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Minetta C Liu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCSF Medical Center-Mission Bay</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94158</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy N. DeLuca</last_name>
      <phone>415-353-7288</phone>
      <email>amy.deluca@ucsf.edu</email>
    </contact>
    <investigator>
      <last_name>Amy N. DeLuca</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MedStar Georgetown University Hospital</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claudine Isaacs</last_name>
      <phone>202-687-2219</phone>
      <email>isaacsc@georgetown.edu</email>
    </contact>
    <investigator>
      <last_name>Claudine Isaacs</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Chicago Comprehensive Cancer Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rita Nanda</last_name>
      <email>rnanda@medicine.bsd.uchicago.edu</email>
    </contact>
    <investigator>
      <last_name>Rita Nanda</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nancy U. Lin</last_name>
      <email>nlin@partners.or</email>
    </contact>
    <investigator>
      <last_name>Nancy U. Lin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan Comprehensive Cancer Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nancy McCullough</last_name>
      <phone>734-936-8538</phone>
      <email>ntsai@med.umich.edu</email>
    </contact>
    <investigator>
      <last_name>Catherine H. Van Poznak</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Minetta C. Liu</last_name>
      <phone>507-293-0526</phone>
      <email>Liu.Minetta@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Minetta C. Liu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UNC Lineberger Comprehensive Cancer Center</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kendalyn Stephens</last_name>
      <phone>919-962-5052</phone>
      <email>kendalyn_stephens@med.unc.edu</email>
    </contact>
    <investigator>
      <last_name>Lisa A. Carey</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Keiana K. Watkins</last_name>
      <phone>919-660-1278</phone>
      <email>breastoncreg@dm.duke.edu</email>
    </contact>
    <investigator>
      <last_name>Keiana K. Watkins</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania/Abramson Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Noah Goodman-Davis</last_name>
      <email>Noah.Goodman@pennmedicine.upenn.edu</email>
    </contact>
    <investigator>
      <last_name>Angela M. DeMichele</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UPMC-Magee Womens Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trisha N. Schneider</last_name>
      <phone>412-641-4706</phone>
    </contact>
    <investigator>
      <last_name>Adam M. Brufsky</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt Breast Center at One Hundred Oaks</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ben H. Park</last_name>
      <phone>800-811-8480</phone>
      <email>ben.h.park@vumc.org</email>
    </contact>
    <investigator>
      <last_name>Ben H. Park</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seattle Cancer Care Alliance</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shaveta Vinayak</last_name>
      <email>broncresearch@seattlecca.org</email>
    </contact>
    <investigator>
      <last_name>Shaveta Vinayak</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>November 8, 2018</study_first_submitted>
  <study_first_submitted_qc>November 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 9, 2018</study_first_posted>
  <last_update_submitted>June 29, 2021</last_update_submitted>
  <last_update_submitted_qc>June 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Ascites</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

